Recent News News

Keytruda Improves Survival of Advanced Bladder Cancer (February 26, 2018)

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of... Continue Reading

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer? (February 22, 2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers... Continue Reading

Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer (February 21, 2018)

A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according... Continue Reading

Diagnosed with Colon Cancer: 10 Tips on How to Get The Most From Your Doctor (February 21, 2018)

1) Choose Your Doctor Carefully Medical oncologists are the primary doctors involved with colon cancer and work in collaboration with surgeons and gastroenterologists. Pick a medical oncologist carefully,... Continue Reading

Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer (February 20, 2018)

CancerConnect News:  Treatment with Cabometyx  (cabozantinib) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could offer... Continue Reading

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer (February 19, 2018)

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food... Continue Reading

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer (February 15, 2018)

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients... Continue Reading

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation (February 14, 2018)

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary... Continue Reading

Keytruda Promising in PD-L1 Esophageal Cancer (February 13, 2018)

CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About... Continue Reading

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer (February 13, 2018)

CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal... Continue Reading

« Previous PageNext Page »